INTRODUCTION {#s1}
============

Lung cancer (LC) caused by multiple risk factors is one of the common malignancies worldwide. With very complex biological characteristics and high degree of invasiveness, it is difficult to diagnose at an early stage and lack of very effective treatment at an advanced stage. Thus, LC is a common public health problem with a poor prognosis. LC involves two major subtypes, such as small cell LC and non-small cell LC (NSCLC). In addition, NSCLC cases account for most of the total LC cases. The increasing incidence of NSCLC is closely related to tobacco consumption, air pollution, cooking fumes, asbestos and other environmental factors \[[@R1]\]. However, these known risk factors might not contribute to overall susceptibility to NSCLC. Recently, individual\'s genetic factors have also been determined to cause NSCLC.

Folic acid, or 5-methyltetrahydrofolate, is a cofactor in the metabolism of homocysteine to methionine \[[@R2]\]. 5,10-ethylenetetrahydrofolate reductase (MTHFR) catalyzed reduction of 5,10-methylenetetrahydrofolate (methylene-THF), a donor of methyl for dUMP to dTMP transform, to methyl-THF, the primary methyl donor in methionine synthesis. Methionine is transformed to S-adenosyl-l-methionine (SAM) which is the principal methyl donor in over 100 biochemical responses, including cytosine methylation in DNA. By the catalysis of DNA (cytosine-5)-methyltransferase, methyl group of SAM was transferred to C5 of cytosine within CpG island in the genomic DNA in higher eukaryotes \[[@R3]--[@R5]\]. MTHFR is a dimeric flavoprotein in human and each monomer is bound to flavinadenosine-dinucleotide noncovalently \[[@R6]\]. Each monomer contains a N-terminal catalytic domain that binds the allosteric SAM inhibitory regulating enzyme activity in response to the methionine levels in the cell \[[@R7]\].The findings of the relationship between methylation patterns and folate status in individuals with cancer and healthy normal individuals provide stronger evidences for a mechanism by which folate may modify DNA methylation and alter the risk of cancer.

Methylenetetrahydrofolate reductase (MTHFR), whose gene maps to the short arm of Chromosome 1 and encodes a 77-kDa protein with 656 amino acids. Many single nucleotide polymorphisms (SNPs) have been identified (<http://www.ncbi.nlm.nih.gov/SNP>), such as rs1801131, rs1801133, rs1537514, rs9651118, rs1537516, rs3753584, rs4845882, rs4846048, rs2066462 and rs3737967 polymorphisms, etc. A number of case-control studies focused on the association between *MTHFR* polymorphisms and the risk of LC \[[@R8]--[@R15]\], however, the results were inconsistent. For example, a meta-analysis suggested that *MTHFR* rs1801133 G\>A was not associated the risk of LC in Chinese population \[[@R16]\]. Nevertheless, Yang *et al.* reported that *MTHFR* rs1801133 G\>A polymorphism increased the risk of lung cancer in Asians, but not in Caucasians \[[@R17]\]. These ambiguous findings may be due to the limited sample size or difference in populations. In order to extensively explore the relationship of *MTHFR* SNPs with LC susceptibility, we selected *MTHFR* tagging SNPs (rs3753584 T\>C, rs4845882 G\>A, rs1801133 G\>A, rs4846048 A\>G and rs9651118 T\>C) and carried out a case-control study to determine the potential effect of *MTHFR* SNPs on NSCLC risk.

RESULTS {#s2}
=======

Baseline characteristics {#s2_1}
------------------------

In this study, a total of 521 sporadic NSCLC patients and 1,030 normal controls were enrolled. Age and sex were full matched (*P* = 0.843 and *P* = 0.453, respectively; Table [1](#T1){ref-type="table"}). Of the NSCLC patients, 287 were male and 234 were female, with a mean age of 59.76 ± 10.71 years. The non-cancer controls were comprised of 588 males and 442 females with a mean age of 60.34 ± 9.11 years. Of the tobacco consumption and drinking and body mass index (BMI), differences were found between NSCLC patients and non-cancer controls (*P* \< 0.001, Table [1](#T1){ref-type="table"}). The genotype distribution of *MTHFR* was calculated after genotyping the 1,551 included participants. For *MTHFR* rs1801133 G\>A, rs4845882 G\>A, rs4846048 A\>G, rs3753584 T\>C and rs9651118 T\>C polymorphisms, success rates of genotyping were 99.87%, 99.94%, 99.94%, 99.94% and 99.94%, respectively (Table [2](#T2){ref-type="table"}). The genotype distribution of *MTHFR* SNPs reached Hardy--Weinberg equilibrium (HWE) in controls, except for *MTHFR* rs4846048 A\>G polymorphism (*P* = 0.036) (Table [2](#T2){ref-type="table"}).

###### Distribution of selected demographic variables and risk factors in NSCLC cases and controls

  Variable         Overall Cases (*n* = 521)   Overall Controls (*n* = 1,030)   *P*^a^
  ---------------- --------------------------- -------------------------------- --------------
  Age (years)      59.76 ± 10.71               60.34 ± 9.11                     0.268
  Age (years)                                                                   0.843
   \< 60           238 (45.68)                 476 (46.21)                      
   ≥ 60            283 (54.32)                 554 (53.79)                      
  Sex                                                                           0.453
   Male            287 (55.09)                 588 (57.09)                      
   Female          234 (44.91)                 442 (42.91)                      
  Smoking status                                                                \< 0.001
   Never           317 (60.84)                 828 (80.39)                      
   Ever            204 (39.16)                 202 (19.61)                      
  Alcohol use                                                                   **\< 0.001**
   Never           444 (85.22)                 949 (92.14)                      
   Ever            77 (14.78)                  81 (7.86)                        
  BMI (kg/m^2^)    23.00 (± 3.03)              23.84 (± 3.06)                   **\< 0.001**
  BMI (kg/m^2^)                                                                 
   \< 24           337 (64.68)                 547 (53.11)                      **\< 0.001**
   ≥ 24            184 (35.32)                 483 (46.89)                      

^a^ Two-sided *χ*^2^ test and Student *t* test

###### Primary information for *MTHFR* polymorphisms (rs1801133 G\>A, rs9651118 T\>C rs4845882 G\>A, rs4846048 A\>G and rs3753584 T\>C)

  Genotyped SNPs                              rs1801133 G\>A   rs3753584 T\>C   rs4845882 G\>A   rs4846048 A\>G   rs9651118 T\>C
  ------------------------------------------- ---------------- ---------------- ---------------- ---------------- ----------------
  Chromosome                                  1                1                1                1                1
  Function                                    Missense         NearGene-5       Intron           Intron           Intron
  Chr Pos (Genome Build 36.3)                 11778965         11787173         11765754         11768839         11784801
  MAF^a^ for Chinese in database              0.439            0.093            0.198            0.105            0.382
  MAF in our controls (***n =*** 1,030)       0.345            0.118            0.214            0.095            0.383
  *P* value for HWE^b^ test in our controls   0.947            0.712            0.454            0.036            0.081
  Genotyping method                           SNPscan          SNPscan          SNPscan          SNPscan          SNPscan
  \% Genotyping value                         99.87%           99.94%           99.94%           99.94%           99.94%

^a^MAF: minor allele frequency;

^b^HWE: Hardy--Weinberg equilibrium

Association of *MTHFR* rs1801133 G\>A, rs4845882 G\>A, rs4846048 A\>G, rs3753584 T\>C and rs9651118 T\>C polymorphisms with the development of NSCLC {#s2_2}
----------------------------------------------------------------------------------------------------------------------------------------------------

Table [3](#T3){ref-type="table"} summarizes the genotypes of *MTHFR* SNPs. *MTHFR* rs1801133 G\>A polymorphism decreased the risk of NSCLC in two genetic models \[AA *vs.* GG: crude odds ratio (OR) = 0.66, 95% confidence interval (CI): 0.45--0.96, *P* = 0.031; and AA *vs.* GA/GG: crude OR = 0.69, 95% CI: 0.48--0.99, *P* = 0.042; Table [3](#T3){ref-type="table"}\]. Adjustment for age, sex, BMI, smoking and drinking, the decreased risk of NSCLC was also found (AA *vs.* GG: adjusted OR = 0.66, 95% CI: 0.47--0.97, *P* = 0.035; Table [3](#T3){ref-type="table"}). However, the above findings were not significant after the Bonferroni correction for multiple comparisons. For *MTHFR* rs3753584 T\>C, rs4845882 G\>A, rs4846048 A\>G and rs9651118 T\>C polymorphisms, we found null association between these SNPs and the risk of NSCLC (Table [3](#T3){ref-type="table"}).

###### Logistic regression analyses of associations between *MTHFR* rs1801133 G\>A, rs3753584 T\>C, rs4845882 G\>A, rs4846048 A\>G and rs9651118 T\>C polymorphisms and the risk of NSCLC

  Genotype                     Cases(*n* = 521)   Controls(*n* = 1,030)   Crude OR(95%CI)   *P*     Adjusted OR ^a^(95%CI)   *P*                                 
  ---------------------------- ------------------ ----------------------- ----------------- ------- ------------------------ ----------- ----------------------- -----------
  ***MTHFR* rs1801133 G\>A**                                                                                                                                     
  GG                           241                46.35                   441               42.86   1.00                                 1.00                    
  GA                           235                45.19                   466               45.29   0.92 (0.74--1.15)        0.467       0.92 (0.73--1.16)       0.461
  AA                           44                 8.46                    122               11.86   **0.66 (0.45--0.96)**    **0.031**   **0.66 (0.44--0.97)**   **0.035**
  GA + AA                      279                53.65                   588               57.14   0.87 (0.70--1.07)        0.192       0.87 (0.70--1.08)       0.207
  GG+ GA                       476                91.54                   907               88.14   1.00                                 1.00                    
  AA                           44                 8.46                    122               11.86   **0.69 (0.48--0.99)**    **0.042**   0.69 (0.47--1.00)       0.050
  A allele                     323                31.06                   710               34.50                                                                
  ***MTHFR* rs3753584 T\>C**                                                                                                                                     
  TT                           403                77.35                   800               77.75   1.00                                 1.00                    
  CT                           111                21.31                   216               20.99   1.02 (0.79--1.32)        0.872       1.03 (0.79--1.35)       0.829
  CC                           7                  1.34                    13                1.26    1.07 (0.42--2.71)        0.885       1.04 (0.39--2.76)       0.937
  CT+CC                        118                22.65                   229               22.25   1.02 (0.80--1.32)        0.860       1.03 (0.79--1.34)       0.826
  TT+CT                        514                98.66                   1,016             98.74   1.00                                 1.00                    
  CC                           7                  1.34                    13                1.26    1.07 (0.42--2.69)        0.894       1.03 (0.39--2.74)       0.948
  C allele                     125                12.00                   242               11.76                                                                
  ***MTHFR* rs4845882 G\>A**                                                                                                                                     
  GG                           309                59.31                   632               61.42   1.00                                 1.00                    
  GA                           191                36.66                   354               34.40   1.11 (0.89--1.38)        0.378       1.12 (0.89--1.42)       0.326
  AA                           21                 4.03                    43                4.18    1.00 (0.58--1.72         0.999       1.14 (0.65--2.01)       0.642
  GA+AA                        212                40.69                   397               38.58   1.09 (0.88--1.35)        0.422       1.12 (0.90--1.10)       0.308
  GG+GA                        500                95.97                   986               95.82   1.00                                 1.00                    
  AA                           21                 4.03                    43                4.18    0.96 (0.57--1.64)        0.891       1.09 (0.63--1.91)       0.753
  A allele                     233                22.36                   440               21.38                                                                
  ***MTHFR* rs4846048 A\>G**                                                                                                                                     
  AA                           428                82.15                   849               82.51   1.00                                 1.00                    
  AG                           90                 17.27                   165               16.03   1.08 (0.82--1.44)        0.578       1.13 (0.84--1.51)       0.423
  GG                           3                  0.58                    15                1.46    0.40 (0.11--1.38)        0.146       0.48 (0.13--1.73)       0.264
  AG+GG                        93                 17.85                   180               17.49   1.03 (0.78--1.35)        0.861       1.08 (0.81--1.44)       0.609
  AA+AG                        518                99.42                   1,014             98.54   1.00                                 1.00                    
  GG                           3                  0.58                    15                1.46    0.39 (0.11--1.36)        0.140       0.47 (0.13--1.70)       0.250
  G allele                     96                 9.21                    195               9.48                                                                 
  ***MTHFR* rs9651118 T\>C**                                                                                                                                     
  TT                           187                35.89                   378               36.73   1.00                                 1.00                    
  TC                           245                47.02                   513               49.85   0.97 (0.77--1.22)        0.783       0.94 (0.74--1.20)       0.636
  CC                           89                 17.08                   138               13.41   1.31 (0.95--1.80)        0.100       1.30 (0.93--1.81)       0.124
  TC+CC                        334                64.11                   651               63.27   1.04 (0.83--1.29)        0.745       1.02 (0.81--1.28)       0.895
  TT+TC                        432                82.92                   891               86.59   1.00                                 1.00                    
  CC                           89                 17.08                   138               13.41   1.33 (1.00--1.78)        0.054       1.34 (0.99--1.82)       0.057
  C allele                     423                40.60                   789               38.34                                                                

^a^ Adjusted for age, sex, smoking, BMI and drinking status; Bold values are statistically significant (*P* \< 0.05).

Association of *MTHFR* rs1801133 G\>A, rs4845882 G\>A, rs4846048 A\>G, rs3753584 T\>C and rs9651118 T\>C polymorphisms with the development of NSCLC in Different Stratification Groups {#s2_3}
---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

After adjustment by logistic regression analysis, we found *MTHFR* rs1801133 G\>A variants were associated with the decreased risk of NSCLC in some subgroups (female group: AA *vs.* GG: adjusted OR = 0.53, 95% CI 0.30--0.94, *P* = 0.031 and AA *vs.* GA/GG: adjusted OR = 0.58, 95% CI 0.33--1.00, *P* = 0.048; \< 60 years subgroup: AA *vs.* GG: adjusted OR = 0.53, 95% CI 0.28--1.00, *P* = 0.048; never smoking group: AA *vs.* GG: adjusted OR = 0.58, 95% CI 0.36--0.93, *P* = 0.024 and AA *vs.* GA/GG: adjusted OR = 0.62, 95% CI 0.39--0.99, *P* = 0.044; Table [4](#T4){ref-type="table"}).

###### Stratified analyses between *MTHFR* rs1801133 G\>A polymorphism and NSCLC risk by sex, age, BMI, smoking status and alcohol consumption

  Variable              MTHFR rs1801133 G\>A (case/control)^a^   Adjusted OR^b^ (95% CI); *P*                                                                                                                  
  --------------------- ---------------------------------------- ------------------------------ -------- ------ ------------------------------ -------------------------------- ------------------------------ --------------------------------
  Sex                                                                                                                                                                                                          
  Male                  125/254                                  136/275                        25/58    1.00   0.99 (0.72--1.35);*P*: 0.930   0.83 (0.48--1.45);*P*: 0.518     0.97 (0.71--1.32);*P*: 0.840   0.84 (0.50--1.43);*P*: 0.527
  Female                116/187                                  99/191                         19/64    1.00   0.85 (0.61--1.20);*P*: 0.357   **0.53 (0.30--0.94);P: 0.031**   0.78 (0.56--1.07);*P*: 0.126   **0.58 (0.33--1.00);P: 0.048**
  Age                                                                                                                                                                                                          
  \< 60                 125/213                                  97/213                         16/49    1.00   0.79 (0.56--1.12);*P*: 0.187   **0.53 (0.28--1.00);P: 0.048**   0.74 (0.53--1.03);*P*: 0.072   0.59 (0.32--1.09);*P*: 0.090
  ≥ 60                  116/228                                  138/253                        28/73    1.00   1.05 (0.77--1.44);*P*: 0.759   0.78 (0.47--1.30);*P*: 0.344     1.01 (0.74--1.36);*P*: 0.976   0.77 (0.47--1.24);*P*: 0.276
  Smoking status                                                                                                                                                                                               
  Never                 153/352                                  137/372                        26/103   1.00   0.86 (0.65--1.14);*P*: 0.298   **0.58 (0.36--0.93);P: 0.024**   0.81 (0.62--1.05);*P*: 0.112   **0.62 (0.39--0.99);P: 0.044**
  Ever                  88/89                                    98/94                          18/19    1.00   1.06 (0.70--1.60);*P*: 0.786   0.92 (0.45--1.90);*P*: 0.829     1.04 (0.70--1.54);*P*: 0.861   0.90 (0.45--1.78);*P*: 0.754
  Alcohol consumption                                                                                                                                                                                          
  Never                 210/411                                  197/426                        36/111   1.00   0.93 (0.72--1.19);*P*: 0.543   0.68 (0.44--1.03);*P*: 0.071     0.88 (0.70--1.12);*P*: 0.293   0.71 (0.47--1.06);*P*: 0.092
  Ever                  31/30                                    38/40                          8/11     1.00   0.88 (0.44--1.75);*P*: 0.711   0.60 (0.21--1.75);*P*: 0.353     0.82 (0.42--1.58);*P*: 0.550   0.65 (0.24--1.75);*P*: 0.393
  BMI (kg/m^2^)                                                                                                                                                                                                
  \< 24                 159/242                                  151/247                        27/57    1.00   0.94 (0.70--1.27);*P*: 0.699   0.68 (0.41--1.15);*P*: 0.149     0.89 (0.67--1.19);*P*: 0.427   0.70 (0.43--1.16);*P*: 0.164
  ≥ 24                  82/199                                   84/219                         17/65    1.00   0.88 (0.61--1.27);*P*: 0.490   0.64 (0.35--1.17);*P*: 0.147     0.84 (0.59--1.19);*P*: 0.323   0.69 (0.38--1.23);*P*: 0.203

^a^ The genotyping was successful in 521 (99.81%) NSCLC cases, and 1030 (99.90%) controls for *MTHFR* rs1801133 G\>A;

^b^ Adjusted for age, sex, BMI, smoking status and alcohol consumption (besides stratified factors accordingly) in a logistic regression model;

The correlation between *MTHFR* rs3753584 T\>C polymorphism and NSCLC risk in the stratified analyses are summarized Table [5](#T5){ref-type="table"}. We found that *MTHFR* rs3753584 T\>C vatiants were not associated with the susceptibility of NSCLC in any subgroup (Table [5](#T5){ref-type="table"}).

###### Stratified analyses between *MTHFR* rs3753584 T\>C polymorphism and NSCLC risk by sex, age, BMI, smoking status and alcohol consumption

  Variable              MTHFR rs3753584 T\>C (case/control)^a^   Adjusted OR^b^ (95% CI); *P*                                                                                                                
  --------------------- ---------------------------------------- ------------------------------ ------ ------ ------------------------------ -------------------------------- ------------------------------ -------------------------------
  Sex                                                                                                                                                                                                        
  Male                  231/450                                  52/127                         4/10   1.00   0.80 (0.54--1.17);*P*: 0.242   0.68 (0.20--2.32);*P*: 0.533     0.78 (0.54--1.14);*P*: 0.201   0.71 (0.21--2.42);*P*: 0.578
  Female                172/350                                  59/89                          3/3    1.00   1.35 (0.92--1.97);*P*: 0.128   2.51 (0.479--12.75);*P*: 0.268   1.38 (0.95--2.01);*P*: 0.093   2.34 (0.46--11.88);*P*: 0.304
  Age                                                                                                                                                                                                        
  \< 60                 181/362                                  54/110                         3/3    1.00   0.95 (0.65--1.40);*P*: 0.806   1.30 (0.25--6.67);*P*: 0.756     0.96 (0.66--1.41);*P*: 0.848   1.31 (0.26--6.73);*P*: 0.745
  ≥ 60                  222/438                                  57/106                         4/10   1.00   1.12 (0.77--1.63);*P*: 0.560   0.89 (0.26--3.04);*P*: 0.855     1.10 (0.76--1.58);*P*: 0.610   0.87 (0.26--2.97);*P*: 0.827
  Smoking status                                                                                                                                                                                             
  Never                 240/650                                  73/168                         4/9    1.00   1.16 (0.84--1.60);*P*: 0.359   1.48 (0.44--5.00);*P*: 0.528     1.18 (0.86--1.61);*P*: 0.314   1.43 (0.43--4.83);*P*: 0.562
  Ever                  163/150                                  38/48                          3/4    1.00   0.77 (0.47--1.25);*P*: 0.281   0.66 (0.14--3.02);*P*: 0.593     0.76 (0.47--1.21);*P*: 0.247   0.70 (0.15--3.20);*P*: 0.645
  Alcohol consumption                                                                                                                                                                                        
  Never                 341/735                                  96/202                         7/11   1.00   0.99 (0.74--1.32);*P*: 0.937   1.43 (0.52--3.92);*P*: 0.489     1.01 (0.76--1.33);*P*: 0.951   1.43 (0.52--3.92);*P*: 0.486
  Ever                  62/65                                    15/14                          0/2    1.00   1.31 (0.56--3.07);*P*: 0.537   \-                               1.08 (0.48--2.45);*P*: 0.852   \-
  BMI (kg/m^2^)                                                                                                                                                                                              
  \< 24                 265/432                                  69/105                         3/9    1.00   1.04 (0.73--1.48);*P*: 0.830   0.47 (0.12--1.84);*P*: 0.278     0.99 (0.70--1.40);*P*: 0.960   0.47 (0.12--1.82);*P*: 0.272
  ≥ 24                  138/368                                  42/111                         4/4    1.00   0.99 (0.65--1.50);*P*: 0.946   3.34 (0.80--14.04);*P*: 0.100    1.06 (0.70--1.59);*P*: 0.788   3.35 (0.80--14.04);*P*: 0.098

^a^ The genotyping was successful in 521 (100.00%) NSCLC cases, and 1030 (99.90%) controls for *MTHFR* rs3753584 T\>C;

^b^ Adjusted for age, sex, BMI, smoking status and alcohol consumption (besides stratified factors accordingly) in a logistic regression model;

The relationship of *MTHFR* rs4845882 G\>A polymorphism with NSCLC susceptibility in the stratified analysis is listed in Table [6](#T6){ref-type="table"}. We identified that *MTHFR* rs4845882 G\>A polymorphism was associated with the development of NSCLC in female subgroup (GA *vs.* GG: adjusted OR = 1.47, 95% CI 1.05--2.05, *P* = 0.025).

###### Stratified analyses between *MTHFR* rs4845882 G\>A polymorphism and NSCLC risk by sex, age, BMI, smoking status and alcohol consumption

  Variable              MTHFR rs4845882 G\>A (case/control)^a^   Adjusted OR^b^ (95% CI); *P*                                                                                                                
  --------------------- ---------------------------------------- ------------------------------ ------- ------ ------------------------------ ------------------------------- ------------------------------ -------------------------------
  Sex                                                                                                                                                                                                        
  Male                  177/349                                  94/212                         16/26   1.00   0.87 (0.63--1.21);*P*: 0.411   1.42 (0.71--2.85);*P*: 0.322    0.93 (0.68--1.26);*P*: 0.627   1.49 (0.75--2.96);*P*: 0.254
  Female                132/283                                  97/142                         5/17    1.00   1.47 (1.05--2.05);P: 0.025     0.68 (0.24--1.90);*P*: 0.460    1.39 (1.00--1.93);*P*: 0.051   0.59 (0.21--1.63);*P*: 0.304
  Age                                                                                                                                                                                                        
  \<60                  136/286                                  92/169                         10/20   1.00   1.17 (0.83--1.65);*P*: 0.361   1.15 (0.50--2.61);*P*: 0.746    1.17 (0.84--1.63);*P*: 0.359   1.08 (0.48--2.42);*P*: 0.862
  ≥60                   173/346                                  99/185                         11/23   1.00   1.07 (0.78--1.47);*P*: 0.685   1.12 (0.52--2.43);*P*: 0.777    1.07 (0.79--1.46);*P*: 0.653   1.09 (0.51--2.35);*P*: 0.820
  Smoking status                                                                                                                                                                                             
  Never                 186/510                                  119/282                        12/35   1.00   1.16 (0.88--1.53);*P*: 0.301   1.09 (0.54--2.18);*P*: 0.815    1.15 (0.88--1.51);*P*: 0.313   1.03 (0.52--2.04);*P*: 0.940
  Ever                  123/122                                  72/72                          9/8     1.00   1.02 (0.68--1.55);*P*: 0.914   1.21 (0.45--3.27);*P*: 0.705    1.04 (0.70--1.56);*P*: 0.842   1.20 (0.45--3.20);*P*: 0.714
  Alcohol consumption                                                                                                                                                                                        
  Never                 260/581                                  168/327                        16/40   1.00   1.14 (0.89--1.45);*P*: 0.312   0.99 (0.53--1.85);*P*: 0.982    1.12 (0.88--1.42);*P*: 0.354   0.95 (0.51--1.75);*P*: 0.858
  Ever                  49/51                                    23/27                          5/3     1.00   0.95 (0.47--1.92);*P*: 0.893   2.23 (0.47--10.67);*P*: 0.315   1.06 (0.54--2.08);*P*: 0.858   2.27 (0.48--10.64);*P*: 0.298
  BMI (kg/m^2^)                                                                                                                                                                                              
  \< 24                 207/338                                  120/190                        10/18   1.00   1.06 (0.78--1.42);*P*: 0.724   1.03 (0.45--2.35);*P*: 0.952    1.05 (0.79--1.41);*P*: 0.737   1.00 (0.44--2.28);*P*: 0.992
  ≥ 24                  102/294                                  71/164                         11/25   1.00   1.24 (0.85--1.79);*P*: 0.262   1.26 (0.58--2.72);*P*: 0.557    1.24 (0.87--1.77);*P*: 0.236   1.16 (0.55--2.48);*P*: 0.697

^a^ The genotyping was successful in 521 (100.00%) NSCLC cases, and 1030 (99.90%) controls for *MTHFR* rs4845882 G\>A;

^b^ Adjusted for age, sex, BMI, smoking status and alcohol consumption (besides stratified factors accordingly) in a logistic regression model;

Table [7](#T7){ref-type="table"} demonstrated that *MTHFR* rs4846048 A\>G polymorphism was not associated with the development of NSCLC in any subgroup.

###### Stratified analyses between *MTHFR* rs4846048 A\>G polymorphism and NSCLC risk by sex, age, BMI, smoking status and alcohol consumption

  Variable              *MTHFR* rs4846048 A\>G (case/control)^a^   Adjusted OR^b^ (95% CI); *P*                                                                                                        
  --------------------- ------------------------------------------ ------------------------------ ------ ------ ---------------------------- ---------------------------- ---------------------------- ----------------------------
  Sex                                                                                                                                                                                                  
  Male                  233/488                                    51/88                          3/11   1.00   1.29(0.86-1.94);*P*: 0.221   0.68(0.18-2.64);*P*: 0.576   1.22(0.83-1.81);*P*: 0.314   0.65(0.17-2.52);*P*: 0.535
  Female                195/361                                    39/77                          0/4    1.00   0.97(0.63-1.49);*P*: 0.884   \-                           0.92(0.60-1.41);*P*: 0.701   \-
  Age                                                                                                                                                                                                  
  \< 60                 191/393                                    47/74                          0/8    1.00   1.45(0.95-2.22);*P*: 0.088   \-                           1.32(0.87-2.00);*P*: 0.197   \-
  ≥ 60                  237/456                                    43/91                          3/7    1.00   0.88(0.59-1.33);*P*: 0.555   0.94(0.23-3.86);*P*: 0.936   0.89(0.60-1.32);*P*: 0.558   0.96(0.24-3.93);*P*: 0.959
  Smoking status                                                                                                                                                                                       
  Never                 262/676                                    53/140                         2/11   1.00   0.98(0.69-1.40);*P*: 0.925   0.60(0.13-2.79);*P*: 0.512   0.96(0.68-1.36);*P*: 0.810   0.60(0.13-2.79);*P*: 0.513
  Ever                  166/173                                    37/25                          1/4    1.00   1.54(0.89-2.68);*P*: 0.126   0.31(0.03-2.87);*P*: 0.302   1.39(0.81-2.36);*P*: 0.230   0.29(0.03-2.67);*P*: 0.274
  Alcohol consumption                                                                                                                                                                                  
  Never                 366/779                                    76/156                         2/13   1.00   1.06(0.77-1.45);*P*: 0.723   0.41(0.09-1.89);*P*: 0.254   1.01(0.75-1.38);*P*: 0.931   0.41(0.09-1.87);*P*: 0.248
  Ever                  62/70                                      14/9                           1/2    1.00   1.95(0.77-4.96);*P*: 0.162   0.57(0.05-7.23);*P*: 0.664   1.70(0.71-4.09);*P*: 0.238   0.52(0.04-6.52);*P*: 0.610
  BMI(kg/m^2^)                                                                                                                                                                                         
  \< 24                 281/455                                    55/86                          1/5    1.00   1.10(0.75-1.62);*P*: 0.629   0.55(0.06-4.92);*P*: 0.591   1.08(0.74-1.57);*P*: 0.708   0.54(0.06-4.83);*P*: 0.579
  ≥ 24                  147/394                                    35/79                          2/10   1.00   1.20(0.76-1.89);*P*: 0.433   0.41(0.08-2.02);*P*: 0.274   1.10(0.71-1.71);*P*: 0.678   0.40(0.08-1.96);*P*: 0.258

^a^The genotyping was successful in 521 (100.00%) NSCLC cases, and 1030 (99.90%) controls for *MTHFR* rs4846048 A\>G;

^b^Adjusted for age, sex, BMI, smoking status and alcohol consumption (besides stratified factors accordingly) in a logistic regression model.

We found that *MTHFR* rs9651118 T\>C polymorphism increased the risk of NSCLC in several stratified analyses (\<60 years group: CC *vs.* TT: adjusted OR = 1.64, 95% CI 1.00--2.69, *P* = 0.049 and CC *vs.* TC/TT: adjusted OR = 1.75, 95% CI 1.12--2.74, *P* = 0.014; never smoking subgroup: CC *vs.* TC/TT: adjusted OR = 1.50, 95% CI 1.05--2.14, *P* = 0.025; BMI \< 24 kg/m^2^ group: CC *vs.*TT: adjusted OR = 1.56, 95% CI 1.01--2.39, *P* = 0.044 and CC *vs.* TC/TT: adjusted OR = 1.56, 95% CI 1.06--2.29, *P* = 0.023; Table [8](#T8){ref-type="table"}).

###### Stratified analyses between *MTHFR* rs9651118 T\>C polymorphism and NSCLC risk by sex, age, BMI, smoking status and alcohol consumption

  Variable         *MTHFR* rs9651118 T\>C (case/control)^a^   Adjusted OR^b^ (95% CI); *P*                                                                                                                
  ---------------- ------------------------------------------ ------------------------------ -------- ------ ------------------------------ ------------------------------ ------------------------------ ------------------------------
  Sex                                                                                                                                                                                                     
  Male             110/209                                    133/300                        44/78    1.00   0.85 (0.61--1.18);*P*: 0.330   1.11 (0.69--1.76);*P*: 0.676   0.90 (0.66--1.23);*P*: 0.503   1.21 (0.79--1.86);*P*: 0.381
  Female           77/169                                     112/213                        45/60    1.00   1.05 (0.73--1.51);*P*: 0.794   1.48 (0.92--2.39);*P*: 0.109   1.15 (0.81--1.61);*P*: 0.435   1.44 (0.94--2.22);*P*: 0.098
  Age                                                                                                                                                                                                     
  \<60             82/163                                     110/255                        46/57    1.00   0.90 (0.62--1.29);*P*: 0.549   1.64 (1.00--2.69);P: 0.049     1.03 (0.73--1.45);*P*: 0.868   1.75 (1.12--2.74);P: 0.014
  ≥60              105/215                                    135/258                        43/81    1.00   1.00 (0.72--1.39);*P*: 1.00    1.05 (0.66--1.65);*P*: 0.848   1.01 (0.74--1.38);*P*: 0.946   1.05 (0.69--1.59);*P*: 0.834
  Smoking status                                                                                                                                                                                          
  Never            111/305                                    146/412                        60/110   1.00   0.93 (0.69--1.25);*P*: 0.646   1.45 (0.98--2.14);*P*: 0.066   1.04 (0.79--1.37);*P*: 0.791   1.50 (1.05--2.14);P: 0.025
  Ever             76/73                                      99/101                         29/28    1.00   0.95 (0.62--1.46);*P*: 0.819   0.97 (0.52--1.80);*P*: 0.918   0.96 (0.64--1.44);*P*: 0.824   1.00 (0.56--1.76);*P*: 0.989
  Never            159/340                                    205/479                        80/129   1.00   0.87 (0.67--1.13);*P*: 0.296   1.25 (0.88--1.78);*P*: 0.212   0.95 (0.74--1.21);*P*: 0.677   1.35 (0.99--1.86);*P*: 0.062
  Ever             28/38                                      40/34                          9/9      1.00   1.66 (0.83--3.30);*P*: 0.153   1.45 (0.49--4.24);*P*: 0.501   1.61 (0.83--3.11);*P*: 0.155   1.11 (0.40--3.03);*P*: 0.845
  BMI (kg/m^2^)                                                                                                                                                                                           
  \< 24            108/187                                    165/287                        64/72    1.00   0.99 (0.72--1.36);*P*: 0.967   1.56 (1.01--2.39);P: 0.044     1.10 (0.81--1.49);*P*: 0.532   1.56 (1.06--2.29);P: 0.023
  ≥ 24             79/191                                     80/226                         25/66    1.00   0.85 (0.58--1.25);*P*: 0.406   0.95 (0.55--1.64);*P*: 0.850   0.87 (0.61--1.25);*P*: 0.456   1.03 (0.62--1.72);*P*: 0.908

^a^The genotyping was successful in 521 (100.00%) NSCLC cases, and 1030 (99.90%) controls for *MTHFR* rs9651118 T\>C;

^b^Adjusted for age, sex, BMI, smoking status and alcohol consumption (besides stratified factors accordingly) in a logistic regression model;

SNP haplotypes {#s2_4}
--------------

Using SHEsis software (<http://analysis.bio-x.cn>) \[[@R18]\], we further constructed seven *MTHFR* haplotypes (Table [9](#T9){ref-type="table"}). Haplotype comparison analysis indicated that *MTHFR* haplotypes were not associated with the risk of NSCLC.

###### *MTHFR* haplotype frequencies (%) in cases and controls and risk of NSCLC

              Case (*n* = 1042)   Control (*n* = 2060)   Crude OR (95% CI)   *P*                         
  ----------- ------------------- ---------------------- ------------------- ------- ------------------- -------
  G T G A C   414                 39.81                  774                 37.63   1.00                
  A T G A T   317                 30.48                  687                 33.40   0.86 (0.72--1.03)   0.105
  G C A A T   121                 11.63                  220                 10.70   1.03 (0.80--1.32)   0.828
  G T A G T   92                  8.85                   185                 8.99    0.93 (0.70--1.23)   0.606
  G T G A T   68                  6.54                   131                 6.37    0.97 (0.71--1.33)   0.853
  G T A A T   13                  1.25                   21                  1.02    1.16 (0.57--2.34)   0.683
  Others      15                  1.44                   39                  1.90    0.72 (0.39--1.32)   0.285

With the order of rs1801133 G\>A, rs3753584 T\>C, rs4845882 G\>A, rs4846048 A\>G and rs9651118 T\>C in gene position.

DISCUSSION {#s3}
==========

In the present study, the relationships of *MTHFR* tagging polymorphisms with the development of NSCLC risk were explored. The results highlighted that *MTHFR* rs1801133 G\>A might decrease the risk of overall NSCLC. In addition, we found *MTHFR* rs1801133 G\>A variants were associated with the decreased risk of NSCLC in female, \< 60 years and never smoking subgroups. However, we found that *MTHFR* rs4845882 G\>A polymorphism was associated with the development of NSCLC in female subgroup. The association between *MTHFR* rs9651118 T\>C polymorphism and the increased the risk of NSCLC was also evident in \< 60 years, never smoking and BMI \< 24 kg/m^2^ subgroups.

Variants of *MTHFR*, which is an important regulator of intracellular folate metabolism, were found that they were associated with the increased level of circulating homocysteine and many diseases involving NSCLC. A number of case-control studies focused on the association of NSCLC with *MTHFR* SNPs and had controversial findings. Recently, a meta-analysis which included twenty-six studies demonstrated that *MTHFR* contribute to the risk of NSCLC in Asians and overall populations, but not Caucasians \[[@R17]\]. Another meta-analysis which enrolled 10 studies with 2487 cases and 3228 controls suggested that rs1801133 G\>A polymorphism in *MTHFR* gene may not be a risk factor of NSCLC in Chinese populations; however, the association between this SNP and NSCLC risk might alter in different region of China \[[@R16]\]. Clearly, these ambiguous findings indicated that the function of *MTHFR* rs1801133 G\>A polymorphism might be varied in different race or even in the different region of the same ethnicity, which suggested large-scale case-control studies in different regions and ethnicities were needed to further explore the potential relationship. It was found that activation and variant frequencies of *MTHFR* might alter among different region and different latitude with the various ultraviolet-exposure levels \[[@R19], [@R20]\]. Furthermore, the sample sizes were relatively small in most of included studies. A functional study indicated that *MTHFR* rs1801133 G\>A polymorphism was a protective factor of prostate cancer (PC) susceptibility by elevating homocysteine level, promoting cell apoptosis, and inhibiting proliferation of PC cells \[[@R21]\]. In the present study, we found that *MTHFR* rs1801133 A allele might be a protective factor for NSCLC, which was similar to the findings of previous study conducted in Eastern Chinese Han populations. However, these potential associations were not significant after the Bonferroni correction for multiple comparisons. Thus, our findings should be explained with very cautions.

Rs4845882 G\>A, a SNP locate in intron region of *MTHFR* gene, was strongly complete linkage disequilibrium (LD) with *MTHFR* rs1801131 A\>C polymorphism \[(*r*2 = 0.935); <http://gvs.gs.washington.edu/GVS147/>\]. Wang *et al.* reported there was no significant correlation between *MTHFR* rs4845882 G\>A polymorphism and gastric cardia carcinoma (GCA) risk \[[@R22]\]. However, another study saw a decreased esophageal squamous cell carcinoma (ESCC) risk in Chinese Han individuals with *MTHFR* rs4845882 AA genotype \[[@R23]\]. In the present study, we found that *MTHFR* 4845882 G\>A might be a risk factor for NSCLC in female subgroup. These inconsistent findings may be due to the limited sample size or other confounding factors. In the future, large-scale study with comprehensive functional exploring should be conducted. And the confounding gene or environmental factors also could not be ignored.

In this study, we found *MTHFR* rs9651118 T\>C polymorphism was associated with the NSCLC risk in some subgroups. And recent case-control studies indicated that this SNP might play different roles among different type of cancer. For example, some studies suggested that *MTHFR* rs9651118 T\>C polymorphism was associated with the decreased susceptibility of LC and PC \[[@R14], [@R24]\]. While Tang *et al*. and Wang *et al.* observed a null association of *MTHFR* rs9651118 T\>C polymorphism with the risk of ESCC and GCA \[[@R22], [@R23]\]. Therefore, whether the T-to-C transition in the intron 2 region does alter the functions of *MTHFR* gene needs to be further explored.

However, several limitations in our study must be acknowledged. Firstly, other functional SNP loci in the region of the *MTHFR* gene may be related to NSCLC susceptibility. Unfortunately, because of genotyping cost, we were unable to perform a fine-mapping study focusing on the association between *MTHFR* SNPs and NSCLC risk. Secondly, the sample size of NSCLC patients was moderate and detailed information of some NSCLC patients was not available. The relationship of *MTHFR* SNPs with tumor stages or cancer subtypes was not carried out. This could limit the validity of the findings because these potentially factors might not be well understood. Thirdly, selected biases might result in spurious findings because the NSCLC patients and the controls were enrolled from the local hospitals. Finally, other potential gene-environment factors were not considered. Further studies focusing on the interactions of multiple environment and gene factors on NSCLC risk are needed to confirm our findings.

In conclusion, the current study highlights *MTHFR* rs1801133 G\>A variants are associated with the decreased risk of NSCLC. However, *MTHFR* rs4845882 G\>A and *MTHFR* rs9651118 T\>C polymorphisms may increase the risk of NSCLC. Well-designed large-scale studies are needed to confirm these findings and explore the interactions of gene-gene and gene-environment involved in *MTHFR* SNPs and NSCLC.

MATERIALS AND METHODS {#s4}
=====================

Ethics Statement {#s4_1}
----------------

This case-control study was conducted in Fujian and Jiangsu Province in Eastern of China. The ethical board approval from Ethics Committee of Fujian Medical University (Fuzhou, China) and Jiangsu University (Zhenjiang, China) was obtained, and all of the participants signed written informed consent.

Subjects {#s4_2}
--------

All sporadic NSCLC patients were enrolled from the Affiliated Union Hospital of Fujian Medical University and the Affiliated People\'s Hospital of Jiangsu University. Our study consisted of 521 NSCLC patients (mean age 59.76 ± 10.71 years) from January 2014 to December 2016. The diagnosis was confirmed based on pathological findings. For comparison, 1,030 non-cancer controls (mean age 60.34 ± 9.11 years) were recruited from normal volunteers who conducted health check in the Physical Examination Center of these hospitals. The controls had no history of autoimmune disorders or personal malignancy, and were frequency well-matched to patients by age and sex. The included risk factors (tobacco consumption and drinking) and demographic details of the NSCLC patients and controls were obtained by using a structured questionnaire. The data are listed in Table [1](#T1){ref-type="table"}.

Preparation of genomic DNA {#s4_3}
--------------------------

Lymphocytes were separated from EDTA-anticoagulated whole blood. Genomic DNA was carefully extracted using the Promega DNA kit (Promega, Madison, USA).

SNP selection {#s4_4}
-------------

SNPs were selected using Haploview 4.2 software and the HapMap database. Five haplotype-tagging SNPs of *MTHFR* gene (rs3753584 T\>C, rs4845882 G\>A, rs1801133 G\>A, rs4846048 A\>G and rs9651118 T\>C) were selected, with MAF \> 5%, call rate ≥ 95 %, HWE *P* ≥ 0.05 and pair-wise r^2^ \< 0.8 for each SNP pair. In total, the five tagging SNPs were selected by spaning the entire *MTHFR* gene region (upstream and downstream extending 5 Kb, respectively). The primary information of the selected SNPs is presented in Table [2](#T2){ref-type="table"}.

Genotyping {#s4_5}
----------

All SNPs were genotyped using the SNPscan^TM^ genotyping assay (Genesky Biotechologies Inc., Shanghai, China), which is a double ligation and multiplex fluorescence PCR \[[@R25]\]. The accuracy of genotyping results were verified by reanalyzing the genotypes in 4% random samples.

Statistical analysis {#s4_6}
--------------------

Age of NSCLC patients and controls was described as the mean ± deviation (SD). And a Student\'s *t*-test was used to examine the difference for age. The deviation from HWE was assessed using an online goodness-of-fit chi-squared test (<http://ihg.gsf.de/cgi-bin/hw/hwa1.pl>) in controls \[[@R26]--[@R32]\]. Using different genetic models (additive, homozygote, dominant, recessive), the genotype frequencies of the subjects were compared using the chi-squared (*χ*^2^) test. Multivariate logistic regression analysis was harnessed to assess the risk of mutant genotype with respect to wild type and considered established confounders such as age, sex, smoking, BMI and drinking status. Crude/adjusted ORs with their 95% CIs were used to assess the difference for the genotype distribution. All data were analyzed using SAS software (Version 9.4; SAS Institute Inc., Cary, NC, USA). SHESIS program (Bio-X Inc., Shanghai, China, <http://analysis.bio-x.cn/myAnalysis.php>)\] \[[@R18]\] was used to construct haplotypes of *MTHFR* gene. The association of *MTHFR* haplotypes with NSCLC risk was estimated as crude ORs with the corresponding 95% CIs. In this study, the threshold for significance was *P* \< 0.05 (two tailed). We used Bonferroni correction to perform multiple comparisons \[[@R33]\].
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